Orzax goes public: Subscription period starts June 29

Orzax, Turkey's leading dietary supplement manufacturer, has received approval from the Capital Markets Board for its initial public offering (IPO), and the relevant documents have been published on the Public Disclosure Platform (KAP). The IPO will be conducted through a consortium led by Info Investment. The subscription period has been set for June 29-30 and July 1. The IPO price is 69 Turkish Lira, and the stock exchange code will be "ORZAX." This development is being closely followed by investors.

With the IPO, Orzax's issued capital is planned to increase from 307 million TL to 338.5 million TL. A total of 31.5 million TL nominal value shares will be offered through a capital increase, while 21 million TL nominal value shares will be offered through a share sale. The free float rate is expected to be 15.51%, and the IPO size is projected to reach 3.62 billion TL. These figures highlight the company's scale and investor interest.

Orzax CEO Yunus Emre Alimoğlu shared the company's post-IPO goals. Stating that they have been operating in the health sector since 2004, Alimoğlu emphasized that they are an R&D-focused institution with high quality standards. He noted that with modern production facilities and a wide product portfolio, they have become a trusted brand not only in Turkey but also in many countries around the world. He expressed that they will continue to grow together with their investors after the IPO.

Alimoğlu also explained the use of proceeds from the IPO. Part of the funds from the capital increase will be used for new investments, R&D center improvements, and expansion in global markets. Another portion will be allocated to working capital needs and increasing financial efficiency. The proceeds from the share sale will be used to close the company's receivable balance from related parties. Thus, the entire 3.6 billion TL will be transferred to Orzax.

Info Investment General Manager Tarkan Akgül stated that the IPO market is strengthening and that it is important to bring qualified companies like Orzax to investors. Emphasizing that Orzax is one of the industry leaders with its high-quality products both domestically and internationally, Akgül expressed his belief that the company will follow a successful path. These statements reinforce confidence in the IPO.